Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 11/20 | 0.66 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.66 |
| ▸ | GRIN2D | O15399 | 9/20 | 0.66 |
| ▸ | GRIN3B | O60391 | 9/20 | 0.66 |
| ▸ | GRIN2A | Q12879 | 9/20 | 0.66 |
| ▸ | GRIN2C | Q14957 | 9/20 | 0.66 |
| ▸ | GRIN3A | Q8TCU5 | 9/20 | 0.66 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577199 | 0.86 | GRIN1 (0.66) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4577677 | 0.85 | GRIN1 (0.66) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4410948 | 0.85 | GRIN1 (0.78) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4576608 | 0.83 | GRIN1 (0.66) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4579765 | 0.82 | MEN1 (0.62) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4578497 | 0.81 | GRIN1 (0.66) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4576699 | 0.81 | GRIN1 (0.66) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4578082 | 0.81 | GRIN1 (0.68) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4578396 | 0.80 | CCR3 (0.64) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL4579066 | 0.80 | GRIN1 (0.64) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021081624-A1 | USE OF GLUTAMATE 2B RECEPTOR ANTAGONISTS AND SIGMA RECEPTOR AGONSISTS AS ANTITUSSIVES | ALGERNON PHARMACEUTICALS INC. (CA) | 2021-05-06 | — | — | WO | disclosed |
| WO-2020163966-A1 | COMPOSITIONS AND METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | ALGERNON PHARMACEUTICALS INC. (CA) | 2020-08-20 | — | — | WO | disclosed |